Loading
A phase 3 trial of Sacituzumab tirumotecan, Pembrolizumab, Gemcitabine and Carboplatin in triple-negative breast cancer, run by Merck Sharp & Dohme LLC, now recruiting.
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011). ClinicalTrials.gov record last updated 2026-10-06: recruiting. Enrollment is planned at 1000 participants. Primary completion is estimated at 2030-05-18. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications. Registered interventions: Sacituzumab tirumotecan, Pembrolizumab, Rescue Medication, Paclitaxel, Nab-paclitaxel, Gemcitabine, Carboplatin. Registered primary measures: Progression-Free Survival (PFS) (sac-TMT versus treatment of physician's choice (TPC); sac-TMT plus pembrolizumab versus TPC); Overall Survival (OS) (sac-TMT versus TPC).
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Sacituzumab tirumotecan, TROP2, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD) and the tag pipeline.
Shares Sacituzumab tirumotecan, TROP2, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD) and the tag pipeline.
Shares Sacituzumab tirumotecan, TROP2, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD) and the tag pipeline.
Shares Sacituzumab tirumotecan, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares TROP2, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD), Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Sacituzumab tirumotecan, Merck & Co. (MSD), Gemcitabine, Pembrolizumab and the tag pipeline.
Shares Merck & Co. (MSD), Gemcitabine, Carboplatin, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Sacituzumab tirumotecan, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD), Antibody-drug conjugate (ADC) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/